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Introduction
The primary targets of fluoroquinolones are DNA gyrase and topoisomerase IV. Both enzymes are tetramers with two different subunits. In pneumococci, fluoroquinolone resistance generally occurs as a result of amino acid substitutions in the quinolone resistance-determining region (QRDR) of these enzymes. In addition, active efflux was found to be a mechanism of resistance to some fluoroquinolones in Streptococcus pneumoniae. Although resistance to the fluoroquinolones remains rare in most countries, the percentage of S. pneumoniae non-susceptible to fluoroquinolones increased from Ͻ0.5% for ofloxacin to 5.5% for levofloxacin (MIC Ͼ 2 mg/L) between 1995 and 1998 in Hong Kong. In this study, fluoroquinolone resistance mechanisms in clinical isolates of S. pneumoniae with increased MICs of ciprofloxacin were characterized. 1 The mutations in gyrA, gyrB, parC and parE associated with fluoroquinolone resistance were determined. The presence of a quinolone efflux mechanism was determined by comparing MICs in the presence and absence of reserpine (a known efflux pump inhibitor).
Materials and methods

Bacterial strains
One-hundred and eighty-one non-duplicate isolates of S. pneumoniae were isolated from consecutive clinical specimens submitted to four hospital laboratories during the second half of 1998. 1 These four laboratories together serve about half of the population in Hong Kong. Of the 181 isolates, 15 ciprofloxacin-resistant and seven ciprofloxacin-susceptible isolates were examined in the present study. The number of isolates from each laboratory was as follows: A (nine isolates), B (two isolates), C (three isolates) and D (eight isolates). All except one (from a patient with bacteraemia) were isolated from sputa of patients with lower respiratory tract infections. Organisms were stored on porous beads at -70ЊC before testing. 
Active efflux of fluoroquinolones
MICs of ciprofloxacin and levofloxacin were determined by the BMD method with and without reserpine (10 mg/L) in cation-adjusted Mueller-Hinton broth supplemented with 2.5% lysed horse blood. MIC determinations were performed at least twice. Discrepant results were repeated. A reproducible reduction of MIC (by two-fold or more) in the presence of reserpine was considered to indicate active efflux.
PCR and DNA sequencing
The QRDRs of gyrA, gyrB, parC and parE were amplified using primers described previously. 4 ,5 Nucleotide sequencing was performed by Bigdye dideoxynucleotide chain termination method using the ABI PRISM 310 Genetic Analyzer (Perkin-Elmer, Foster City, CA, USA). For all the isolates, the sequences of both strands of the amplicons were determined.
Results
The Table shows the MICs of four quinolone antibiotics, together with the efflux phenotype and mutations in the gyrA, gyrB, parC and parE genes for 22 isolates of S. pneumoniae. All MICs were reproducible on repeated testing. Efflux of ciprofloxacin was found in 6/7 of the ciprofloxacin-susceptible and 14/15 ciprofloxacin-resistant isolates. Efflux of levofloxacin was found in 3/12 levofloxacinsusceptible and 4/10 levofloxacin-non-susceptible isolates. In GyrA, eight isolates had mutations that resulted in Ser-81 being substituted by phenylalanine. No amino acid change was detected in GyrB. Sixteen isolates had at least one amino acid substitution in ParC and seven of these had two substitutions, being a S79F or Y plus K137N pair. In ParE, 20/22 isolates had at least one substitution, and three of these had two and one had three substitutions.
Discussion
This study revealed target site modifications in all the isolates with reduced susceptibility to fluoroquinolones. Similar to mutants selected in the laboratory, most of the amino acid substitutions in the QRDR were present in ParE and ParC, while few changes occurred in GyrA.
Resistance that occurs as a result of substitutions in GyrA alone is not commonly encountered in clinical isolates. Of 69 isolates examined by Jones et al., 6 only five had a single amino acid substitution in GyrA alone. In the present study, all GyrA substitutions were found in the levofloxacin-resistant (MIC у 8 mg/L) isolates, and they occurred together with various substitutions in ParC and ParE. In comparison, group 2 isolates with changes in ParC and ParE alone remained susceptible to levofloxacin. These findings thus suggested that first-step mutants (ParC and ParE) might be an initial stage in the development of high-level fluoroquinolone resistance, which has arisen in vivo by an additional GyrA substitution. Gene sequencing of gyrA, parC and parE in this study shows that substitutions with a possible association with quinolone resistance in clinical strains of pneumococci are S81F in GyrA, S79F, S79Y and K137N in ParC, and D435N, P454S, I460V and E474K in ParE. Similar to previous reports, 6 the two classical substitutions, S81F in GyrA and S79F or Y in ParC, were clearly associated with resistance among our strains. This study shows that ParE substitutions, including I460V, E474K and D435N, are not obviously associated with significant resistance to any of the fluoroquinolones. Absence of effect on susceptibility for I460V and D435N in ParE has been reported by some, 6,7 while others 8 found that they might produce low-level resistance to some fluoroquinolones. Although K137N in ParC was suggested to be unimportant, 6 our finding indicated that the S81F (GyrA) ϩ K137N (ParC) pair can bring about resistance to levofloxacin, trovafloxacin and moxifloxacin. Nonetheless, the effect of double mutations in ParC (S79F or Y and K137N) with and without S81F in GyrA did not seem to be additive.
This study identified reserpine-inhibited efflux of ciprofloxacin in almost all the ciprofloxacin-susceptible and -resistant isolates, similar to that reported earlier.
7 Efflux of levofloxacin was also common, although at a lower frequency in both levofloxacin-susceptible and levofloxacinnon-susceptible isolates. This study and those of others 7 indicate that antimicrobial drug efflux on its own is not a common cause of high-level resistance. It might, however, facilitate mutational resistance by permitting short-term bacterial survival. mococci. Seven had chronic obstructive pulmonary disease. Six patients had been treated with one or more fluoroquinolones [ofloxacin (2/6), ciprofloxacin (2/6) and levofloxacin (5/6)] before isolation of these organisms. In conclusion, increasing MICs to a panel of fluoroquinolones were associated with accumulation of target site modifications in those strains with a reserpine-inhibited efflux mechanism. To prevent resistance development, the use of efflux-susceptible and the less active fluoroquinolones for pneumococcal infection should be avoided. 
